NRG-LU001: Randomized Phase II Trial of Concurrent Chemoradiotherapy +/- Metformin HCL in Locally Advanced NSCLC; NCT02186847

Read Press Release 

View Slide Presentation

Principal Investigators   

 Theodoros (Theos) Tsakiridis, MD

 Heath Skinner, MD, PhD

Primary Objective

To determine whether metformin added to chemoradiotherapy can improve progression-free survival in patients with locally advanced NSCLC

Patient Population

Pathologically proven diagnosis of Stage IIIA or IIIB non-small cell lung cancer; patients must have unresectable disease, be medically inoperable, or not willing to undergo surgical management.

Target Accrual

168 patients


Activated  August  25, 2014

Protocol Documents

 The protocol and related documents are available at NRG-LU001


Copyright 2017 by NRG Oncology